Ann: Investor Presentation, page-34

Haha go slow with enrollments? Have enrollments been fast over the past few years?

It's clear they needed to redesign the trial. I remember previously working out they were on track to complete phase 1b enrollment in 2028 if the enrollment rate stayed the same as it had been. It was just taking far too long.

At least CDH17 has broader patient population and ease of administration (compared to CLTX, it is still an autologous CAR-T therapy after all). So hopefully well see a bit more data from that trial over the next year or two.